Farther Finance Advisors LLC Raises Holdings in Merck & Co., Inc. $MRK

Key Points

• Farther Finance Advisors boosted its Merck stake by 48.9% in Q4 to 97,818 shares worth $10.296M, and institutional investors now own about 76.07% of MRK.
• Insiders have been net sellers recently, disposing of 320,176 shares worth roughly $38.28M in the last three months (insiders now own 0.13% of the stock), including a $14.49M sale by EVP Jennifer Zachary.
• Regulatory and analyst catalysts are in play: the FDA granted priority review for Merck/Daiichi’s ifinatamab deruxtecan in extensive‑stage small cell lung cancer, while brokers have raised price targets and the consensus rating is "Moderate Buy" with an average target of $128.47.

Farther Finance Advisors LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 48.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,818 shares of the company's stock after buying an additional 32,114 shares during the quarter. Farther Finance Advisors LLC's holdings in Merck & Co., Inc. were worth $10,296,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Chemung Canal Trust Co. lifted its holdings in shares of Merck & Co., Inc. by 21.1% in the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company's stock worth $6,407,000 after acquiring an additional 13,285 shares during the last quarter. First Pacific Financial lifted its holdings in shares of Merck & Co., Inc. by 14.7% in the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company's stock worth $3,991,000 after acquiring an additional 6,082 shares during the last quarter. Diversified Trust Co lifted its holdings in shares of Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company's stock worth $17,444,000 after acquiring an additional 18,187 shares during the last quarter. Coldstream Capital Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 12.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after acquiring an additional 13,940 shares during the last quarter. Finally, Campbell Capital Management Inc. acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $1,866,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP David Michael Williams sold 5,000 shares of the firm's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the sale, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. This trade represents a 13.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the firm's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. NYSE: MRK Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA XTRA: MRK appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA XTRA: MRK Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here's Why

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MRK. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. Guggenheim upped their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a report on Friday, February 6th. TD Cowen upped their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a "hold" rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $128.47.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $118.07 on Thursday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company's 50 day moving average is $119.26 and its two-hundred day moving average is $105.51. The firm has a market cap of $291.62 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the business earned $1.72 EPS. The company's revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 46.70%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.